Navigation Links
Data from In Vivo Disease Models on Taligen Therapeutics' Pipeline Candidates to be Presented at the XXII International Complement Workshop
Date:9/25/2008

Presentations Include Proof-of-Concept Animal Data on Previously Disclosed Fusion Protein TT30 and New Molecules TT32 and mAb171

CAMBRIDGE, Mass., Sept. 25 /PRNewswire/ -- Taligen Therapeutics Inc. today announced that data from in vivo disease models on several of the company's pipeline candidates will be presented next week at the XXII International Complement Workshop in Basel, Switzerland.

The data, which will be presented in eight oral and poster presentations, are the results of research conducted by the laboratories of Michael Holers, M.D., chief scientific officer of Taligen, and the company's academic collaborators in the complement research community. Five studies testing the company's fusion protein TT30 and two new compounds, a fusion protein TT32 and a monoclonal antibody mAb171, in animal models are highlighted below. These data further support Taligen's approach that targeting the alternative complement pathway can impact complement-mediated inflammatory disease processes.

Poster Presentations:

TT30

Targeted inhibition of the alternative pathway by CR2-fH fusion protein ameliorates progression of renal disease in MRL/lpr mice

Hideharu Sekine*, Gary Gilkeson, Stephen Tomlinson

Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 174

Alternative complement pathway signaling in a mouse model of choroidal neovascularisation

Barbel Rohrer*, Qin Long, Brooks Wilson, Beth Coughlin, Yuxiang Huang, Fei Qiao, Peter Tang, Kannan Kunchithapautham, Gary Gilkeson, Stephen Tomlinson

Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 202

TT30 and TT32

Targeted complement-inhibitory proteins CR2-Crry and CR2-fH ameliorate allergen-induced airway hyperresponsiveness and inflammation

Joshua Thurman*, Katsuyuki Takeda, Stephen Tomlinson, Erwin Gelfand, V. Michael Holers

Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 171

The role
'/>"/>

SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
2. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
3. Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
4. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
5. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
6. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
7. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
8. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
9. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
10. Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
11. SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 Quantum ... scaling volume production of photoactive quantum dots for ... . While offering numerous advantages for solar power ... large quantities of quantum dots with which to ... kept them from commercial utilization and acceptance. The ...
(Date:10/1/2014)... 1, 2014  SI-BONE, Inc., a medical device company that ... a minimally invasive surgical (MIS) device indicated for fusion for ... expansion of its European operations with the formation of a ... as General Manager, Germany.  Mr. Schaber will join former Kyphon ... Europe , Middle East ...
(Date:10/1/2014)... R.I. , Oct. 1, 2014  CVS Health ... Month for their role in changing the way health ... improve quality in the Company,s retail pharmacies, mail service ... month, we changed our company name to CVS Health ... expertise in driving the innovations needed to shape the ...
Breaking Medicine Technology:Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3
... Nov. 23 Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) ... U.S. Food and Drug Administration (FDA) on January 20, 2010 ... Application (NDA) for Intermezzo ® (zolpidem tartrate ... by Transcept on October 28, 2009, indicated that the FDA ...
... , ORANGE COUNTY, Calif., Nov. 23 ... a leading developer, manufacturer, and marketer of products that ... that Allan Harris, Beckman Coulter,s vice president of strategy, ... Wednesday, December 2, 2009 at 12:00 p.m. (ET). , ...
Cached Medicine Technology:Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter 2
(Date:10/1/2014)... October 01, 2014 First Warning Systems, ... circadian cellular changes throughout the body, announced the company ... better address the company’s breadth of upcoming product releases. ... cancer screening technology. , “Our initial focus will be ... which detects abnormal circadian cellular changes over time,” said ...
(Date:10/1/2014)... 01, 2014 Join the more than 80 ... Treatment Center’s first ever charity golf tournament to benefit Project ... eating disorders who cannot afford treatment. The tournament will be ... Eureka, Mo. , The day-long event starts with 10:30 ... and award dinner will begin at 5 p.m. and will ...
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations ... October 20, 2014 at 7:30 a.m. EST/PT via Discovery ... the scenes to learn about Break the Cycle’s comprehensive ... practical help and information Break the Cycle provides to ... of abuse, how to navigate the legal system, and ...
(Date:10/1/2014)... 2014 Scientists at the University of ... target immune system proteins has the power to knock ... details of the new study on their website. ... Researchers in the UWA School of Pathology and Laboratory ... mice with mesothelioma with promising results. , “A ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 October is ... awareness and early detection plans while raising money for ... support Breast Cancer Awareness Month in the effort ... wants to promote the importance of having access to ... water may be linked to certain forms of cancer. ...
Breaking Medicine News(10 mins):Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2
... Attorneys from Dallas, Rasansky Law Firm are ... of the mother of a 2-year-old girl who choked to death ... lawsuit includes claims that the day care,s owners quickly sold the ... from showing up on a state licensing database. , According to ...
... WAYNE, Pa., Nov. 5 Qualsec,s (OTC Bulletin ... received an order from DMC Athletics & ... business will offer products of QLSZ,s wholly-owned subsidiary, ... providing dietary support to their various wellness programs. ...
... DUE TO AN EMBARGO BREAK , From their very first days, ... speak, reveals a new study published online on November 5th in ... that infants begin picking up elements of what will be their ... babble or coo. "The dramatic finding of this study is ...
... left demanding jobs report the most improvement, study finds, , ... doing once retired seems to make a good night,s ... French workers who had retired found that the odds of ... 26 percent lower than in the seven years before they ...
... Research Institute calls for further investigations into the use of ... Nov. 5 Two studies published by the Southwest College ... Clinical Pharmacology investigated the use of oral dimercaptosuccinic acid ... lead poisoning, and used off-label in these studies for treating ...
... ... for the ClearCanvas customer base of more than 5,000 radiology software users worldwide. ... Toronto, Ontario (PRWEB) ... premier support provider for ClearCanvas, Inc. open source RIS/PACS products. Oso Healthcare ...
Cached Medicine News:Health News:The Rasansky Law Firm Announces Dallas Day Care Death Lawsuit; State Investigation Finds Evidence of Negligence at Woodbridge Day School 2Health News:Qualsec's Wholly-Owned Subsidiary Receives Order From New Jersey-Based DMC Athletics and Rehabilitation 2Health News:Babies' language learning starts from the womb 2Health News:Without Job Stress, Retirees Sleep Better 2Health News:Chelation Therapy Drug Found Safe and Beneficial for Children With Autism 2Health News:Oso Healthcare Provides Implementation and Support Services for ClearCanvas Open Source RIS/PACS 2Health News:Oso Healthcare Provides Implementation and Support Services for ClearCanvas Open Source RIS/PACS 3Health News:Oso Healthcare Provides Implementation and Support Services for ClearCanvas Open Source RIS/PACS 4
Help restore pelvic muscle function with the Prometheus Pathway CTS 2000 evaluation and training system....
... catheters with secondary sensors placed in the ... test also provides information about acid control ... stomach or proximal esophageal acid exposure and ... Ability to record pH simultaneously in up ...
... the advance of digital imaging technology, ... towards digital formats, allowing for easier ... advance in digital pathology imaging is ... in radiology, and which is continuing ...
... SONOLINE G40 ultrasound system brings,the benefits ... entirely new level of diagnostic performance,and ... that meets your clinical needs. With ... and pulsed-wave Doppler capabilities,the G40 system ...
Medicine Products: